US R&D

AbbVie has reached a landmark deal with the Trump administration, committing billions to U.S. R&D and capital investments over a decade. The agreement includes lower prices for Medicaid beneficiaries and expanded direct-to-patient access through “TrumpRx.” This pact, exempting AbbVie from tariffs and future price mandates, aims to balance domestic investment with drug affordability, supporting innovation and patient access.